4.7 Article

Anewly identified complex of spinophilin and the tyrosine phosphatase, SHP-1, modulates platelet activation by regulating G protein-dependent signaling

期刊

BLOOD
卷 119, 期 8, 页码 1935-1945

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-10-387910

关键词

-

资金

  1. National Institutes of Health [HL40387, HL93123, GM39561, T32 HL07439]
  2. American Heart Association [0525630U]

向作者/读者索取更多资源

Platelets are essential for normal hemostasis, but close regulation is required to avoid the destructive effects of either inappropriate platelet activation or excessive responses to injury. Here, we describe a novel complex comprising the scaffold protein, spinophilin (SPL), and the tyrosine phosphatase, SHP-1, and show that it can modulate platelet activation by sequestering RGS10 and RGS18, 2 members of the regulator of G protein signaling family. We also show that SPL/RGS/SHP1 complexes are present in resting platelets where constitutive phosphorylation of SPL(Y398) creates an atypical binding site for SHP-1. Activation of the SHP-1 occurs on agonist-induced phosphorylation of SHP-1(Y536), triggering dephosphorylation and decay of the SPL/RGS/SHP1 complex. Preventing SHP-1 activation blocks decay of the complex and produces a gain of function. Conversely, deleting spinophilin in mice inhibits platelet activation. It also attenuates the rise in platelet cAMP normally caused by endothelial prostacyclin (PGI(2)). Thus, we propose that the role of the SPL/RGS/SHP1 complex in platelets is time and context dependent. Before injury, the complex helps maintain the quiescence of circulating platelets by maximizing the impact of PGI(2). After injury, the complex gradually releases RGS proteins, limiting platelet activation and providing a mechanism for temporal coordination of pro thrombotic and antithrombotic inputs. (Blood. 2012;119(8):1935-1945)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells

S. A. Misek, K. M. Appleton, T. S. Dexheimer, E. M. Lisabeth, R. S. Lo, S. D. Larsen, K. A. Gallo, R. R. Neubig

ONCOGENE (2020)

Article Pharmacology & Pharmacy

Mice with GNAO1 R209H Movement Disorder Variant Display Hyperlocomotion Alleviated by Risperidone

Casandra L. Larrivee, Huijie Feng, Josiah A. Quinn, Vincent S. Shaw, Jeffrey R. Leipprandt, Elena Y. Demireva, Huirong Xie, Richard R. Neubig

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)

Review Cell Biology

Use of electron microscopy to study platelets and thrombi

Maurizio Tomaiuolo, Rustem I. Litvinov, John W. Weisel, Timothy J. Stalker

PLATELETS (2020)

Article Biophysics

Microfluidic-assisted nanoprecipitation of biodegradable nanoparticles composed of PTMC/PCL (co)polymers, tannic acid and doxorubicin for cancer treatment

Marek Brzezinski, Marta Socka, Tomasz Makowski, Bartlomiej Kost, Marcin Cieslak, Karolina Krolewska-Golinska

Summary: This study developed a novel microfluidic approach for preparing (co)polymeric and hybrid nanoparticles, which showed great potential in drug release and inhibition of breast cancer cells. The composition of PCL/TA NPs demonstrated the most efficient antitumor activity among all formulations, surpassing the efficacy of free DOX.

COLLOIDS AND SURFACES B-BIOINTERFACES (2021)

Article Biochemistry & Molecular Biology

New Succinimides with Potent Anticancer Activity: Synthesis, Activation of Stress Signaling Pathways and Characterization of Apoptosis in Leukemia and Cervical Cancer Cells

Marcin Cieslak, Mariola Napiorkowska, Julia Kazmierczak-Baranska, Karolina Krolewska-Golinska, Anna Hawryl, Iwona Wybranska, Barbara Nawrot

Summary: In this study, a series of 26 new dicarboximide derivatives were designed and synthesized, showing high to moderate cytotoxicity in cancer cells and upregulation of apoptotic genes. The derivatives also activated MAPKs signaling pathway, indicating potential as novel anticancer drugs.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Oncology

Inhibition of the Myocardin-Related Transcription Factor Pathway Increases Efficacy of Trametinib in NRAS-Mutant Melanoma Cell Lines

Kathryn M. Appleton, Charuta C. Palsuledesai, Sean A. Misek, Maja Blake, Joseph Zagorski, Kathleen A. Gallo, Thomas S. Dexheimer, Richard R. Neubig

Summary: In NRAS mutant melanoma cells, activation of the Rho pathway is associated with high intrinsic resistance to the MEK inhibitor trametinib. Combining a Rho/MRTF pathway inhibitor with trametinib can synergistically reduce cell viability and induce apoptosis in resistant melanoma cells. Targeting both the Rho/MRTF pathway and MEK shows therapeutic potential in NRAS mutant melanomas.

CANCERS (2021)

Article Hematology

Thrombin spatial distribution determines protein C activation during hemostasis and thrombosis

Tanya T. Marar, Chelsea N. Matzko, Jie Wu, Charles T. Esmon, Talid Sinno, Lawrence F. Brass, Timothy J. Stalker, Maurizio Tomaiuolo

Summary: Researchers found that the spatial distribution of thrombin plays a crucial role in the activation of protein C during hemostasis and thrombosis. This study utilized pharmacological, genetic, imaging, and computational approaches to investigate the relationship between thrombin distribution, protein C activation, and anticoagulant function.
Article Biochemistry & Molecular Biology

Selenium-Containing Exopolysaccharides Isolated from the Culture Medium of Lentinula edodes: Structure and Biological Activity

Sandra Gorska-Jakubowska, Marzenna Klimaszewska, Piotr Podsadni, Beata Kaleta, Radoslaw Zagozdzon, Sabina Gorska, Andrzej Gamian, Tomasz Straczek, Czeslaw Kapusta, Marcin Cieslak, Julia Kazmierczak-Baranska, Barbara Nawrot, Jadwiga Turlo

Summary: The selenium-enriched polysaccharides from fungal sources exhibit immunomodulatory and antioxidant activities, enhancing cell viability and inhibiting the proliferation of human peripheral blood mononuclear cells, but with lower activity compared to selenium-containing mycelial isolates.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Neurosciences

Mice with monoallelic GNAO1 loss exhibit reduced inhibitory synaptic input to cerebellar Purkinje cells

Huijie Feng, Yukun Yuan, Michael R. Williams, Alex J. Roy, Jeffery R. Leipprandt, Richard R. Neubig

Summary: This study investigates the electrophysiological mechanisms of a movement disorder animal model with monoallelic Gnao1 loss. It reveals the role of G alpha(o) protein in regulating GABA release in the mouse cerebellum. The findings could lead to the discovery of new drugs or the repurposing of existing drugs for GNAO1-associated disorders. Additionally, targeting GNAO1 could have implications for the treatment of other monogenic movement disorders.

JOURNAL OF NEUROPHYSIOLOGY (2022)

Article Engineering, Chemical

Gold(I) Complexes with P-Donor Ligands and Their Biological Evaluation

Monika Richert, Renata Mikstacka, Mariusz Walczyk, Marcin Janusz Cieslak, Julia Kazmierczak-Baranska, Karolina Krolewska-Golinska, Tadeusz Mikolaj Muziol, Stanislaw Biniak

Summary: Gold(I) complexes with phosphine ligands were investigated as bioactive gold metallodrugs, with complex (2) showing the most promising biological properties including high stability, selectivity towards cancer cells, and the highest inhibitory effect on cytosolic NADPH-dependent reductases.

PROCESSES (2021)

Article Oncology

Novel Dicarboximide BK124.1 Breaks Multidrug Resistance and Shows Anticancer Efficacy in Chronic Myeloid Leukemia Preclinical Models and Patients' CD34+/CD38- Leukemia Stem Cells

Iga Stukan, Marek Gryzik, Grazyna Hoser, Andrew Want, Wioleta Grabowska-Pyrzewicz, Mikolaj Zdioruk, Mariola Napiorkowska, Marcin Cieslak, Karolina Krolewska-Golinska, Barbara Nawrot, Grzegorz Basak, Urszula Wojda

Summary: Chemotherapy is widely used for cancer treatment but often leads to therapy resistance. This study discovered that the novel compound BK124.1 can overcome chemotherapy resistance in chronic myeloid leukemia. BK124.1 showed efficacy in animal and cellular models, targeting multidrug resistant leukemia blasts and cancer stem cells. Future development of BK124.1 could offer a cure for chronic myeloid leukemia and other chemotherapy-resistant cancers.

CANCERS (2022)

Article Biochemistry & Molecular Biology

Targeting ATP12A, a Nongastric Proton Pump a Subunit, for Idiopathic Pulmonary Fibrosis Treatment

Mohamed Abdelgied, Katie Uhl, Oliver G. Chen, Chad Schultz, Kaylie Tripp, Angela M. Peraino, Shreya Paithankar, Bin Chen, Maximiliano Tamae Kakazu, Alicia Castillo Bahena, Tara E. Jager, Cameron Lawson, Dave W. Chesla, Nikolay Pestov, Nikolai N. Modyanov, Jeremy Prokop, Richard R. Neubig, Bruce D. Uhal, Reda E. Girgis, Xiaopeng Li

Summary: Idiopathic pulmonary fibrosis (IPF) is a pathological condition with unknown cause that leads to lung injury and fibrotic response, resulting in thickening of alveolar walls and obliteration of alveolar space. Small airway disease and mucus accumulation are prominent in IPF lungs, similar to cystic fibrosis lung disease. Overexpression of the ATP12A protein in distal small airways of IPF patients and in mouse lungs exacerbates pulmonary fibrosis, which can be prevented by vonoprazan, a potassium competitive proton pump blocker. Inhibiting ATP12A protein may serve as a novel therapeutic strategy for IPF.

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2023)

Article Hematology

Novel Strategy to Combat the Procoagulant Phenotype in Heparin-Induced Thrombocytopenia Using 12-LOX Inhibition

Stephanie A. Renna, Xuefei Zhao, Satya P. Kunapuli, Peisong Ma, Michael Holinstat, Matthew B. Boxer, David J. Maloney, James V. Michael, Steven E. Mckenzie

Summary: This study investigated the cooperativity of PARs (protease-activated receptors) and Fc & gamma;RIIA in HIT using human and mouse model systems. It was found that pharmacological inhibition of 12-LOX can decrease platelet procoagulant phenotype and reduce thrombocytopenia and thrombosis in a mouse model of HIT.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2023)

Review Pharmacology & Pharmacy

Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?

Marcin Cieslak, Marta Slowianek

Summary: The traditional low-molecular-weight drugs target specific biological targets with receptor or enzymatic activity to inhibit their function. However, there are disease proteins that cannot be targeted using this approach. PROTACs, on the other hand, can bind both the protein of interest and the E3 ubiquitin ligase complex, leading to degradation. This review focuses on PROTACs recruiting CRBN E3 ubiquitin ligase and targeting various proteins involved in tumorigenesis.

PHARMACEUTICS (2023)

Article Chemistry, Multidisciplinary

Development of a Cell-Based AlphaLISA Assay for High-Throughput Screening for Small Molecule Proteasome Modulators

Sophia D. Staerz, Erika M. Lisabeth, Evert Njomen, Thomas S. Dexheimer, Richard R. Neubig, Jetze J. Tepe

Summary: The balance between protein degradation and synthesis, proteostasis, is key for proper cellular function. The majority of intracellular protein degradation occurs through the ubiquitin-proteasome system, with pathways targeting unfolded proteins playing an important role. Dysregulation of proteolysis can lead to the accumulation of intrinsically disordered proteins (IDPs), contributing to various diseases. Enhancing the activity of the 20S proteasome using small molecules, such as erlotinib, has shown potential in combating IDP accumulation.

ACS OMEGA (2023)

暂无数据